These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 14710235)

  • 1. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
    Okubo S; Kurebayashi J; Otsuki T; Yamamoto Y; Tanaka K; Sonoo H
    Br J Cancer; 2004 Jan; 90(1):236-44. PubMed ID: 14710235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
    Kurebayashi J; Okubo S; Yamamoto Y; Sonoo H
    Breast Cancer; 2004; 11(1):38-41. PubMed ID: 14718791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
    Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
    Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
    McClelland RA; Barrow D; Madden TA; Dutkowski CM; Pamment J; Knowlden JM; Gee JM; Nicholson RI
    Endocrinology; 2001 Jul; 142(7):2776-88. PubMed ID: 11415996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
    Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
    Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
    Garon EB; Pietras RJ; Finn RS; Kamranpour N; Pitts S; Márquez-Garbán DC; Desai AJ; Dering J; Hosmer W; von Euw EM; Dubinett SM; Slamon DJ
    J Thorac Oncol; 2013 Mar; 8(3):270-8. PubMed ID: 23399957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
    Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
    Nicholson RI; Hutcheson IR; Harper ME; Knowlden JM; Barrow D; McClelland RA; Jones HE; Wakeling AE; Gee JM
    Ann N Y Acad Sci; 2002 Jun; 963():104-15. PubMed ID: 12095935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X; Diaz MR; Yee D
    Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.
    Dowsett M; Nicholson RI; Pietras RJ
    Breast Cancer Res Treat; 2005; 93 Suppl 1():S11-8. PubMed ID: 16247595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
    Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
    Magné N; Fischel JL; Tiffon C; Formento P; Dubreuil A; Renée N; Formento JL; Francoual M; Ciccolini J; Etienne MC; Milano G
    Br J Cancer; 2003 Aug; 89(3):585-92. PubMed ID: 12888834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H; Cheng D; Weichel AK; Osipo C; Wing LK; Chen B; Louis TE; Jordan VC
    Int J Oncol; 2006 Nov; 29(5):1237-46. PubMed ID: 17016657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.
    Camirand A; Zakikhani M; Young F; Pollak M
    Breast Cancer Res; 2005; 7(4):R570-9. PubMed ID: 15987464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Takabatake D; Fujita T; Shien T; Kawasaki K; Taira N; Yoshitomi S; Takahashi H; Ishibe Y; Ogasawara Y; Doihara H
    Int J Cancer; 2007 Jan; 120(1):181-8. PubMed ID: 17036319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.